These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8532725)

  • 21. Phenobarbital does not promote hepatic tumorigenesis in a twenty-six-week bioassay in p53 heterozygous mice.
    Sagartz JE; Curtiss SW; Bunch RT; Davila JC; Morris DL; Alden CL
    Toxicol Pathol; 1998; 26(4):492-500. PubMed ID: 9715508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Report of ICPEMC Task Group 5 on the differentiation between genotoxic and non-genotoxic carcinogens.
    Mutat Res; 1984 Jan; 133(1):1-49. PubMed ID: 6363908
    [No Abstract]   [Full Text] [Related]  

  • 23. Interactions in the tumor-promoting activity of carbon tetrachloride, trichloroacetate, and dichloroacetate in the liver of male B6C3F1 mice.
    Bull RJ; Sasser LB; Lei XC
    Toxicology; 2004 Jul; 199(2-3):169-83. PubMed ID: 15147791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice.
    Yamamoto Y; Moore R; Goldsworthy TL; Negishi M; Maronpot RR
    Cancer Res; 2004 Oct; 64(20):7197-200. PubMed ID: 15492232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impacts of chemicals on liver cancer risk.
    Wogan GN
    Semin Cancer Biol; 2000 Jun; 10(3):201-10. PubMed ID: 10936069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An improved long-term culture of rat hepatocytes to detect liver tumour-promoting agents: results with phenobarbital.
    Mesnil M; Piccoli C; Yamasaki H
    Eur J Pharmacol; 1993 Jun; 248(1):59-66. PubMed ID: 8393408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans: evidence for a glycoprotein factor that facilitates hepatic tumor progression.
    Bhaumik M; Harris T; Sundaram S; Johnson L; Guttenplan J; Rogler C; Stanley P
    Cancer Res; 1998 Jul; 58(13):2881-7. PubMed ID: 9661906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic mechanisms of liver tumor promotion.
    Williams GM
    Prog Clin Biol Res; 1990; 331():131-45; discussion 147-8. PubMed ID: 2179956
    [No Abstract]   [Full Text] [Related]  

  • 29. Liver cell cancer: insights into the pathogenesis of hepatocellular carcinoma in humans from experimental hepatocarcinogenesis in the rat.
    Farber E
    Monogr Pathol; 1987; (28):199-222. PubMed ID: 3023976
    [No Abstract]   [Full Text] [Related]  

  • 30. Mouse models to study the interaction of risk factors for human liver cancer.
    Sell S
    Cancer Res; 2003 Nov; 63(22):7553-62. PubMed ID: 14633666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.
    Wells MY; Williams ES
    Regul Toxicol Pharmacol; 2009 Mar; 53(2):150-5. PubMed ID: 19126422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do mouse liver tumors predict rat tumors? A study of concordance between tumors induced at different sites in rats and mice.
    Byrd DM; Crouch EA; Wilson R
    Prog Clin Biol Res; 1990; 331():19-41. PubMed ID: 2315341
    [No Abstract]   [Full Text] [Related]  

  • 33. Mouse liver tumors: relevance to human cancer risks. Symposium of the European Society of Toxicology. Rome, February 2-5, 1986. Proceedings.
    Arch Toxicol Suppl; 1987; 10():1-295. PubMed ID: 3472495
    [No Abstract]   [Full Text] [Related]  

  • 34. The connection of β-catenin and phenobarbital in murine hepatocarcinogenesis: a critical discussion of Awuah et al., PLoS ONE 7(6):e39771, 2012.
    Braeuning A
    Arch Toxicol; 2013 Mar; 87(3):401-2. PubMed ID: 23266721
    [No Abstract]   [Full Text] [Related]  

  • 35. Current and emerging challenges in toxicopathology: carcinogenic threshold of phenobarbital and proof of arsenic carcinogenicity using rat medium-term bioassays for carcinogens.
    Fukushima S; Morimura K; Wanibuchi H; Kinoshita A; Salim EI
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):225-9. PubMed ID: 15993454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetically altered mouse models for identifying carcinogens.
    Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
    IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
    [No Abstract]   [Full Text] [Related]  

  • 37. Understanding arsenic carcinogenicity by the use of animal models.
    Wanibuchi H; Salim EI; Kinoshita A; Shen J; Wei M; Morimura K; Yoshida K; Kuroda K; Endo G; Fukushima S
    Toxicol Appl Pharmacol; 2004 Aug; 198(3):366-76. PubMed ID: 15276416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion.
    Counts JL; Goodman JI
    Prog Clin Biol Res; 1995; 391():81-101. PubMed ID: 8532739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of DNA adduct formation by phenobarbital, polychlorinated biphenyls, and chlordane in mouse liver using the 32P-postlabeling assay.
    Whysner J; Montandon F; McClain RM; Downing J; Verna LK; Steward RE; Williams GM
    Toxicol Appl Pharmacol; 1998 Jan; 148(1):14-23. PubMed ID: 9465259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rainbow trout (Oncorhynchus mykiss) tumor model: recent applications in low-dose exposures to tumor initiators and promoters.
    William DE; Bailey GS; Reddy A; Hendricks JD; Oganesian A; Orner GA; Pereira CB; Swenberg JA
    Toxicol Pathol; 2003; 31 Suppl():58-61. PubMed ID: 12597433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.